Emerging drugs for the treatment of gastrointestinal stromal tumors: a spotlight on bezuclastinib and the evolving treatment landscape.

Pozas J, Napolitano A, Jones RL

Open source

DOI
10.1080/14728214.2026.2739621
Published
2026 Sep 25
Container
Expert opinion on emerging drugs
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14728214.2026.2739621,
  title = {Emerging drugs for the treatment of gastrointestinal stromal tumors: a spotlight on bezuclastinib and the evolving treatment landscape.},
  author = {Pozas J and Napolitano A and Jones RL},
  year = {2026},
  journal = {Expert opinion on emerging drugs},
  doi = {10.1080/14728214.2026.2739621},
  url = {https://doi.org/10.1080/14728214.2026.2739621}
}

RIS

TY  - JOUR
TI  - Emerging drugs for the treatment of gastrointestinal stromal tumors: a spotlight on bezuclastinib and the evolving treatment landscape.
AU  - Pozas J
AU  - Napolitano A
AU  - Jones RL
PY  - 2026
JO  - Expert opinion on emerging drugs
DO  - 10.1080/14728214.2026.2739621
UR  - https://doi.org/10.1080/14728214.2026.2739621
ER  - 

APA

J, P., A, N., & RL, J. (2026). Emerging drugs for the treatment of gastrointestinal stromal tumors: a spotlight on bezuclastinib and the evolving treatment landscape.. Expert opinion on emerging drugs. https://doi.org/10.1080/14728214.2026.2739621

Source records